Flashea 112 analyzer

All the chemicals used for synthesis were of Merck, Sigma, Research lab, Qualigens make and Himedia. The reactions were carried out by conventional method and in synthetic microwave oven (Milestone micro synth). Melting points were determined in open capillaries using melting point apparatus and are uncorrected. All the reactions were performed in oven-dried glassware. Phosphorus oxychloride was used by distilling under reduced pressure. The synthetic protocol employed for the synthesis of N-((5-(substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl) benzamide derivatives 7(a–l) is presented in Scheme 1. The purity of the synthesized compounds was checked by TLC, and melting points were determined in open capillary tubes and are uncorrected. The NMR spectra of the final titled compounds N-((5-(substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl) benzamide were recorded on Brucker Advance II (400 MHz), and Infrared (IR) spectra were recorded for the compounds on JASCO FTIR (PS 4000, JASCO, Tokyo, Japan) using KBr pallet. The mass spectra were recorded on a Waters Micro Mass (ZQ 2000 spectrometer, UK). Elemental analyses were done with a FLASHEA 112 Shimadzu’ analyzer (Mumbai, Maharashtra, India) and all analyses were consistent (within 0.4%) with theoretical values.

All the reactions were performed in oven-dried glasswares. All reagents and solvents were used as obtained from the supplier or recrystallized/redistilled unless otherwise noted. The ultrasound sonicator (Sonics Vibra-cell, Modelno. VCX 500, Newtown, CT, USA) equipped with solid synthetic probe, 13 mm in tip diameter, operating at 20 kHz with a maximum power output of 500 W, was used for synthesis of final title compounds. The purity of the synthesized compounds was monitored by ascending thin layer chromatography (TLC) on silica gel-G (Merck, Darmstadt, Germany) coated aluminum plates, visualized by iodine vapor and melting points were determined in open capillary tubes. Infrared (IR) spectra were recorded on a PS 4000 FTIR (JASCO, Tokyo, Japan) using KBr pellets. Elemental analyses (C, H, and N) were done with a FLASHEA 112 Shimadzu’ analyzer (Mumbai, Maharashtra, India) and all analyses were consistent (within 0.4%) with theoretical values. The ¹H-NMR and ¹³C-NMR spectra of synthesized compounds were recorded on Bruker Avance II 400 NMR Spectrometer (Billerica, MA, USA) at 400 MHz Frequency in deuterated DMSO and CDCl₃ and using TMS as internal standard (chemical shift δ in ppm). Mass spectra of some compounds were scanned on FTMS + p ESI full mass (100.00–1500.00).

The FTIR spectra were obtained by means of a FTIR-4000 instrument (JASCO, Tokyo, Japan) and peaks were given in terms of wave number (cm⁻¹). The ¹H-NMR and ¹³C-NMR spectra of the synthesized compounds were recorded on an Avance II 400 NMR spectrometer (Bruker, Biospin AG Industriestrasse 26, CH-8117, Fallanden, Switzerland)at 400/100 MHz frequency in CDCl₃ and using TMS as internal standard (chemical shift δ in ppm). The ³¹P-NMR spectra of compounds were recorded in CDCl₃ using phosphoric acid (H₃PO₄) as external standard (chemical shift δ in ppm). The mass spectra were executed on a Micromass Q-Tof system (Waters, UK). Elemental analyses were done with a FLASHEA 112 analyzer (Shimadzu, Mumbai, Maharashtra, India) and all analyses were consistent (within 0.4%) with theoretical values. A Vibra Cell VCX-500 ultrasound synthesizer (Sonics, Newtown, CT, USA) equipped with a solid probe was employed for the synthesis of intermediate 1. In vitro anti-cancer activity screening of the synthesized compounds was accomplished at the Anti-Cancer Drug screening facility (ACDSF) at ACTREC (Tata Memorial Centre, Navi Mumbai, India).